Press Releases Shattuck Labs, Inc.

Equities

STTK

US82024L1035

Market Closed - Nasdaq Other stock markets 04:00:00 2024-06-03 pm EDT			5-day change	1st Jan Change
7.33 ^USD	-0.68%		-2.14%	+2.81%

May. 14	Shattuck Labs to Present Additional Data from the Phase 1B Dose Expansion Clinical Trial of Sl-172154 with Azacitidine in Frontline Higher-Risk Myelodysplastic Syndromes (Hr-Mds) and Tp53 Mutant Acute Myeloid Leukemia Patients At the European Hematology Association 2024 Congress	CI
May. 02	Shattuck Labs, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2024	CI

Press Releases

Unlock all the news: Be the first to know and act before the market!

100% Free Registration

Shattuck Labs to Present Additional Data from the Phase 1B Dose Expansion Clinical Trial of SL-172154 with Azacitidine (AZA) in Frontline Higher-Risk Myelodysplastic Syndromes (HR-MDS) and TP53 mutant (TP53m) Acute Myeloid Leukemia (AML) Patients at the European Hematology Association (EHA) 2024 Congress	May. 14	GL
Shattuck Labs : May 02, 2023 Shattuck Labs Corporate Presentation	May. 02	PU
Shattuck Labs Reports First Quarter 2024 Financial Results and Recent Business Highlights	May. 02	GL
Shattuck Labs Announces Oral Presentation of Preclinical Data at the American Association for Cancer Research (AACR) Annual Meeting 2024	Apr. 09	GL
Shattuck Labs Announces Participation in Upcoming 23rd Annual Needham Virtual Healthcare Conference	Apr. 01	GL
Shattuck Labs Announces Appointment of Clay Siegall, Ph.D., and Kate Sasser, Ph.D., to its Board of Directors	Mar. 04	GL
Shattuck Labs Announces Appointment of Clay Siegall, Ph.D., and Kate Sasser, Ph.D., to its Board of Directors	Mar. 04	AQ
Shattuck Labs Reports Fourth Quarter and Full-Year 2023 Financial Results and Recent Business Highlights	Feb. 29	GL
Shattuck Labs Reports Fourth Quarter and Full-Year 2023 Financial Results and Recent Business Highlights	Feb. 29	AQ
Shattuck Labs Announces Participation in Upcoming March Conferences	Feb. 26	GL
Ono Enters into a Drug Discovery Collaboration and Option Agreement with Shattuck Labs to Generate Bifunctional Fusion Proteins	Feb. 14	PR
Shattuck Labs Enters into Strategic Collaboration and License Agreement with Ono Pharmaceutical to Generate Bifunctional Fusion Proteins for the Treatment of Autoimmune and Inflammatory Diseases	Feb. 13	GL
Shattuck Labs Enters into Strategic Collaboration and License Agreement with Ono Pharmaceutical to Generate Bifunctional Fusion Proteins for the Treatment of Autoimmune and Inflammatory Diseases	Feb. 13	AQ
Shattuck Labs Provides Corporate Update and Highlights Upcoming Key Milestones in 2024	Jan. 08	GL
Shattuck Labs Provides Corporate Update and Highlights Upcoming Key Milestones in 2024	Jan. 08	AQ
Shattuck Labs Announces Presentation at Upcoming 42nd Annual J.P. Morgan Healthcare Conference	Jan. 04	GL
Shattuck Labs Announces $50 Million Public Offering of Common Stock and Concurrent Private Placement of Pre-Funded Warrants	Dec. 21	GL
Shattuck Labs Announces $50 Million Public Offering of Common Stock and Concurrent Private Placement of Pre-Funded Warrants	Dec. 21	AQ
Shattuck Labs Announces Positive Initial Topline Data from Ongoing Phase 1 A/B Dose Expansion Clinical Trial of SL-172154 with Azacitidine in Frontline Higher-Risk Myelodysplastic Syndromes (HR-MDS) and TP53 mutant (TP53m) Acute Myeloid Leukemia (AML) Patients	Dec. 13	GL
Shattuck Labs to Host Investor Call and Webcast to Share Initial Clinical Trial Data from Phase 1A/B Dose-Expansion Cohorts in Frontline Higher-Risk Myelodysplastic Syndromes (HR-MDS) and TP53m Acute Myeloid Leukemia (AML) and Review of Dose-Escalation Data from the American Society of Hematology (ASH) 2023 Annual Meeting on December 13, 2023	Dec. 05	GL

No results for this search

All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

Press Releases Shattuck Labs, Inc.

Equities

STTK

US82024L1035

Press Releases

Filters